Sign In
Buy CHRS
$1.46
-0.0200 (-1.35%)
At Close: Jun 23, 2026
Coherus Biosciences Shows Rising Relative Price Performance; Still Working On Building Base
09:39pm, Tuesday, 21'st Apr 2020
A Relative Strength Rating upgrade for Coherus Biosciences shows improving technical performance. Will it continue?
Coherus: Branded Biosimilar Strategy, Cash Reserve, Revenue Stream
03:01pm, Tuesday, 21'st Apr 2020
Coherus has a strong revenue generating pipeline and 4 upcoming product candidates. It has good cash reserve and just recently did a secondary. It seems like a
SunTrust Banks Begins Coverage on Coherus Biosciences (NASDAQ:CHRS)
09:48am, Tuesday, 21'st Apr 2020
SunTrust Banks started coverage on shares of Coherus Biosciences (NASDAQ:CHRS) in a report released on Friday morning, Benzinga reports. The brokerage issued a buy rating and a $26.00 price target on
Coherus Biosciences Shows Rising Relative Price Performance; Still Shy Of Key Benchmark
12:00am, Tuesday, 21'st Apr 2020Coherus Biosciences: Worth The Risks
12:46pm, Monday, 20'th Apr 2020
Based on the explosive growth expected in the biosimilar market and this company’s recent successful biosimilar launch, I am bullish on Coherus Biosciences. Wit
Mizuho Securities Remains a Buy on Gilead Sciences (GILD)
02:01pm, Friday, 17'th Apr 2020
Mizuho Securities analyst Salim Syed maintained a Buy rating on Gilead Sciences (GILD) today and set a price target of $81.00. The company's shares closed
Mizuho Securities Remains a Buy on Gilead Sciences (GILD)
02:00pm, Friday, 17'th Apr 2020
Mizuho Securities analyst Salim Syed maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a
Coherus Biosciences initiated with a Buy at SunTrust CHRS
11:42am, Friday, 17'th Apr 2020
Coherus Biosciences initiated with a Buy at SunTrust SunTrust CHRS
SunTrust Robinson Humphrey Initiates Coverage On Coherus BioSciences with Buy Rating, Announces Price Target to $26
11:27am, Friday, 17'th Apr 2020Benchmark likes Regeneron in premarket analyst action
11:18am, Friday, 17'th Apr 2020
Axovant Gene Therapies (NASDAQ:AXGT) initiated with an Overweight rating and a $11 (209% upside) price target at Cantor Fitzgerald.Bicycle Therapeutics (NASDAQ:BCYC) initiated with a Buy rating and a
Don't Waste Your Money on Penny Stocks, These 2 Stocks Are Better Buys
11:16am, Friday, 17'th Apr 2020
These healthcare stocks are risky, but they offer investors much better wealth-building potential than penny stocks.
Coherus Biosciences initiated with a Buy at SunTrust CHRS
11:04am, Friday, 17'th Apr 2020
Coherus Biosciences initiated with a Buy at SunTrust SunTrust CHRS
Check These 7 Top-Ranked Stocks With Solid Net Profit Margins
11:27am, Thursday, 16'th Apr 2020
Let's take a look at the seven top-ranked stocks with impressive net profit margins for a winning portfolio.
Check These 7 Top-Ranked Stocks With Solid Net Profit Margins
11:27am, Thursday, 16'th Apr 2020
Let's take a look at the seven top-ranked stocks with impressive net profit margins for a winning portfolio.
